📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Migraine Drugs Companies

Migraine is a neurological disorder characterized by recurrent headaches, often accompanied by sensory disturbances and other symptoms. There are several pharmaceutical companies that have developed and marketed drugs for the prevention and treatment of migraines.

Migraine Drugs Key CompaniesLatest Migraine Drugs Companies Update

March 2023: Pfizer Inc. disclosed that ZAVZPRET™, the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, has received approval from the U.S. Food and Drug Administration (FDA). It is indicated for the acute treatment of migraine in adults, with or without aura. At two hours after the dose, ZAVZPRET was statistically superior to placebo in its pivotal Phase 3 study with regard to the co-primary endpoints of pain relief and absence of the most bothersome symptom. In contrast to the placebo group, the pivotal study also demonstrated pain relief within 15 minutes, as measured by a predetermined secondary endpoint. ZAVZPRET highlights Pfizer's dedication to providing an additional therapeutic alternative that can assist individuals with migraine in attaining alleviation and resuming their routine activities.

February 2023: A majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company specializing in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain, Scilex Holding Company, declared the commercial launch of ELYXYBTM in the United States in February 2023. Customers can obtain ELYXYBTM from pharmacies, where it is supplied via the standard wholesaler and distributor channels. The U.S. Food and Drug Administration (FDA) approved ELYXYBTM for the treatment of acute migraine in adults, aura or no aura included. Proficient re-launch commercialization endeavors, comprising over six thousand interactions with prospective clients and five posters at the American Headache Society (AHS), have established the foundation for what Scilex anticipates to be a triumphant re-introduction of ELYXYBTM into the outpatient market.List of Migraine Drugs Key companies in the market

  • Allergan Plc (Ireland)

  • Alder Biopharmaceuticals Inc. (US)

  • Pfizer Inc. (US)

  • GlaxoSmithKline Plc (UK)

  • Merck & Co. Inc. (US)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • AstraZeneca PLC (UK)

  • Johnson & Johnson Services Inc. (US)

  • Amgen Inc. (US)

  • Eli Lilly and Company

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.